ArticleCurrent medicinal chemistry2026
Cyasterone Improves Mitochondrial Function and Protects against Knee Osteoarthritis by Activating PPARγ.
Article in Current medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
introductionStudies have demonstrated that mitochondrial dysfunction plays an important role in the development of knee osteoarthritis. Our previous study reported that cyasterone accelerates fracture healing by promoting the migration and osteogenesis of mesenchymal stem cells (MSCs). However, the effect of cyasterone on osteoarthritis (OA) has not been investigated. Therefore, this study aimed to investigate the effects of cyasterone on mitochondrial function in chondrocytes of mice and its potential therapeutic impact on knee osteoarthritis (OA) in mice.
methodsPrimary chondrocytes were isolated from C57BL/6 mice, and the optimal cyasterone concentration was determined via CCK-8 assay. An osteoarthritis chondrocyte model was established using lipopolysaccharide (LPS) induction. Chondrocytes were assigned to control, LPS, and cyasterone treatment groups. ATP production, NAD+/NADH ratio, oxidative stress levels, and mitochondrial membrane potential were measured in each group. Adult C57BL/6 mice were allocated into three groups (n=8 per group): control, model, and cyasterone treatment. After 4 weeks of cyasterone intervention, histopathological changes in knee joints and expression of extracellular matrix-related proteins in cartilage tissue were assessed.
resultsCompared to the LPS group, cyasterone treatment significantly increased ATP production, elevated the NAD+/NADH ratio, and reduced oxidative stress levels in LPS- induced chondrocytes. Mechanically, we found that the expression of Peroxisome proliferator- activated receptor γ (PPARγ) was significantly increased by cyasterone. In the OA group treated with cyasterone, the mice exhibited marked improvement in cartilage histopathological scores compared to the model group, with enhanced expression of aggrecan and PPARγ proteins and decreased expression levels of MMP13 and phosphorylated- p65. DISCUSSION: Consistent with previous findings, our results showed that cyasterone significantly increased PPARγ expression in primary chondrocytes, thereby maintaining chondrocyte function and preventing the progression of OA.
conclusionIn summary, the results indicated that cyasterone could restore mitochondrial function in LPS-induced mouse chondrocytes by upregulating PPARγ expression. in vivo, cyasterone was found to reduce extracellular matrix degradation and inhibit the progression of osteoarthritis (OA). These findings suggest that cyasterone could be a potential natural compound for the effective treatment of OA.
Indexed as
Identifiers
41837479What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.